Samsung Biologics Co.,Ltd. 207940.KS · Stock Open Samsung Biologics Co.,Ltd. in new tab
Samsung Biologics Co.,Ltd. Analysis (207940.KS)
Is Samsung Biologics Co.,Ltd. a good investment? Samsung Biologics Co.,Ltd. (207940.KS) is currently trading at 1000000.00 KRW.
Earnings Schedule: Samsung Biologics Co.,Ltd. is expected to release its next earnings report on July 29, 2026.
Investor FAQ
Does Samsung Biologics Co.,Ltd. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Samsung Biologics Co.,Ltd.?
Samsung Biologics Co.,Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be July 29, 2026.
Company Profile
Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Community Discussion